A RANDOMIZED, MULTICENTER, DOUBLE BLIND, PHASE III STUDY OF ADJUVANT NIVOLUMAB OR PLACEBO IN SUBJECTS WITH RESECTED LOWER ESOPHAGEAL, OR GASTROESOPHAGEAL JUNCTION CANCER.
SAFETY AND EFFICACY OF A LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTIN IDIOPATHIC PULMONARY FIBROSISA MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF THE SAFETY ANDEFFICACY OF BMS-986020 IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS
A RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, COMPARATIVE PHASE III STUDY OF ORAL BMS-284756 VERSUS ORAL AZITHROMVCIN IN THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS
100 Clinical Results associated with Bristol-Myers Squibb Peru SA
0 Patents (Medical) associated with Bristol-Myers Squibb Peru SA
100 Deals associated with Bristol-Myers Squibb Peru SA
100 Translational Medicine associated with Bristol-Myers Squibb Peru SA